Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients. (2024)
Attributed to:
MICA: Pharmacokinetic/Pharmacodynamic (PKPD) Model Development to Inform SARS-CoV-2 Antiviral Development
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.clim.2024.109901
PubMed Identifier: 38218209
Publication URI: http://europepmc.org/abstract/MED/38218209
Type: Journal Article/Review
Volume: 259
Parent Publication: Clinical immunology (Orlando, Fla.)
ISSN: 1521-6616